论文部分内容阅读
一项新的研究发现,血管紧张素转化酶抑制剂(ACEI)用于治疗心衰时所需的剂量要比目前所用的剂量高很多。3月30日在亚特兰大举行的美国心脏学会议上,ATLAS试验显示高剂量(32.5～35mg.d-1)赖诺普利(lisinopril,Zestril)比临床实践中普遍采用的低剂量(2.5～5mg.d-1)对临床长期预后
A new study found that angiotensin converting enzyme inhibitors (ACEI) for the treatment of heart failure when the dose required than the current dose is much higher. At the American Heart Association conference in Atlanta on March 30, the ATLAS trial showed that high doses (32.5-35 mg.d-1) of lisinopril (Zestril) were less common than low-dose (2.5-5 mg .d-1) on clinical long-term prognosis